PET and SPECT in cardiovascular molecular imaging

Nature Reviews Cardiology

Volumn 7, Issue 1, 2010, Pages 38-47

  Dobrucki, Lawrence W ^a   Sinusas, Albert J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 3 HYDROXYEPHEDRINE; ACETIC ACID; ADENOVIRUS VECTOR; ALPHA ADRENERGIC RECEPTOR; ARGINYLGLYCYLASPARTIC ACID; BETA ADRENERGIC RECEPTOR; BLOOD CLOTTING FACTOR 8; BROMINE 76; CARBON 11; COPPER 64; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INDIUM 111; IODINE 123; IODINE 124; LACTIC ACID; LISINOPRIL; MATRIX METALLOPROTEINASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NANOPARTICLE; PALMITIC ACID; PHENYLEPHRINE; RADIOISOTOPE; TECHNETIUM 99M; UNINDEXED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG HALF LIFE; DRUG METABOLISM; EARLY DIAGNOSIS; ECHOGRAPHY; GENE THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; IMAGE DISPLAY; IMAGE PROCESSING; IMAGE QUALITY; IMAGING SYSTEM; IONIZING RADIATION; ISOTOPE LABELING; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOLECULAR IMAGING; MOLECULAR PROBE; MYOCARDIAL DISEASE; NEUROENDOCRINE SYSTEM; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOCHEMISTRY; REPORTER GENE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; THREE DIMENSIONAL IMAGING; X RAY;

ANIMALS; ATHEROSCLEROSIS; CARDIAC-GATED SINGLE-PHOTON EMISSION COMPUTER-ASSISTED TOMOGRAPHY; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; GENES, REPORTER; HUMANS; MOLECULAR IMAGING; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENSORY RECEPTOR CELLS; VENTRICULAR REMODELING;

EID: 76849098682     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.201     Document Type: Review

References (90)

1. National Academy of Engineering. Greatest Engineering Achievements of the 20th Century [online], http://www.greatachievements.org (2009).
2. Brumley, C. L. & Kuhn, J. A. Radiolabeled monoclonal antibodies. Aorn J. 62, 343-350 (1995).
3. inubushi, M. & Tamaki, N. Radionuclide reporter gene imaging for cardiac gene therapy. Eur. J. Nucl. Med. Mol. Imaging 34 (Suppl. 1), S27-S33 (2007).
4. Sun, N., Lee, A. & Wu, J. C. Long term non-invasive imaging of embryonic stem cells using reporter genes. Nat. Protoc. 4, 1192-1201 (2009).
5. Willmann, J. K. et al. imaging gene expression in human mesenchymal stem cells: from small to large animals. Radiology 252, 117-127 (2009).
6. Hiona, A. & Wu, J. C. Noninvasive radionuclide imaging of cardiac gene therapy: progress and potential. Nat. Clin. Pract. Cardiovasc. Med. 5 (Suppl. 2), S87-S95 (2008).
7. Nahrendorf, M. et al. Multimodality cardiovascular molecular imaging, part ii. Circ. Cardiovasc. Imaging 2, 56-70 (2009).
8. Sinusas, A. J. et al. Multimodality cardiovascular molecular imaging, part i. Circ. Cardiovasc. Imaging 1, 244-256 (2008).
9. Dobrucki, L. W. & Sinusas, A. J. Molecular imaging. A new approach to nuclear cardiology. Q. J. Nucl. Med. Mol. Imaging 49, 106-115 (2005).
10. Dobrucki, L. W. & Sinusas, A. J. Molecular cardiovascular imaging. Curr. Cardiol. Rep. 7, 130-135 (2005).
11. Dobrucki, L. W. & Sinusas, A. J. Cardiovascular molecular imaging. Semin. Nucl. Med. 35, 73-81 (2005).
12. Dobrucki, L. W. & Sinusas, A. J. imaging angiogenesis. Curr. Opin. Biotechnol. 18, 90-96 (2007).
13. Blankenberg, F. G. Molecular imaging: The latest generation of contrast agents and tissue characterization techniques. J. Cell. Biochem. 90, 443-453 (2003).
14. Sinusas, A. J. imaging of angiogenesis. J. Nucl. Cardiol. 11, 617-633 (2004).
15. Morrison, A. R. & Sinusas, A. J. New molecular imaging targets to characterize myocardial biology. Cardiol. Clin. 27, 329-344 (2009).
16. Kim, H. et al. SemiSPECT: a small-animal singlephoton emission computed tomography (SPECT) imager based on eight cadmium zinc telluride (CZT) detector arrays. Med. Phys. 33, 465-474 (2006).
17. Wagenaar, D. J., Kapusta, M., Li, J. & Patt, B. E. Rationale for the combination of nuclear medicine with magnetic resonance for preclinical imaging. Technol. Cancer Res. Treat. 5, 343-350 (2006).
18. Tawakol, A. et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48, 1818-1824 (2006).
19. Dilsizian, v. et al. Metabolic imaging with beta-methyl-p-[(123)i]- iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 112, 2169-2174 (2005).
20. Kida, K., Akashi, Y. J., Yoneyama, K., Shimokawa, M. & Musha, H. 123i-BMiPP delayed scintigraphic imaging in patients with chronic heart failure. Ann. Nucl. Med. 22, 769-775 (2008).
21. Nakamura, A. et al. Ability of (201)Tl and (123)i-BMiPP mismatch to diagnose myocardial ischemia in patients with suspected coronary artery disease. Ann. Nucl. Med. doi:10.1007/ s12149-009-0307-0308
22. Nanasato, M. et al. Restored cardiac conditions and left ventricular function after parathyroidectomy in a hemodialysis patient. Parathyroidectomy improves cardiac fatty acid metabolism assessed by 123i-BMiPP. Circ. J. 73, 1956-1960 (2009).
23. Shi, C. Q. et al. Correlation of myocardial p-(123)i- iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia. J. Nucl. Med. 43, 421-431 (2002).
24. verani, M. S. et al. 123i-iPPA SPECT for the prediction of enhanced left ventricular function after coronary bypass graft surgery. Multicenter iPPA viability Trial investigators. 123i-iodophenylpentadecanoic acid. J. Nucl. Med. 41, 1299-1307 (2000).
25. volokh, L., Lahat, C. & Blevis, i. Myocardial perfusion imaging with an ultra-fast cardiac SPECT camera: a phantom study. Nuclear Science Symposium Conference Record 19-25 October 4636-4639 (2008).
26. Levy, M. N. Cardiac sympatheticparasympathetic interactions. Fed. Proc. 43, 2598-2602 (1984).
27. Sunagawa, K., Kawada, T. & Nakahara, T. Dynamic nonlinear vago-sympathetic interaction in regulating heart rate. Heart Vessels 13, 157-174 (1998).
28. Zemaityte, D. J., varoneckas, G. A. & Sokolov, E. N. interaction between the parasympathetic and sympathetic divisions of the autonomic nervous system in cardiac rhythm regulation. Hum. Physiol. 11, 208-215 (1985).
29. Henneman, M. M., Bengel, F. M., van der Wall, E. E., Knuuti, J. & Bax, J. J. Cardiac neuronal imaging: application in the evaluation of cardiac disease. J. Nucl. Cardiol. 15, 442-455 (2008).
30. Higuchi, T. & Schwaiger, M. Noninvasive imaging of heart failure: neuronal dysfunction and risk stratification. Heart Fail. Clin. 2, 193-204 (2006).
31. Carrio, i. Cardiac neurotransmission imaging. J. Nucl. Med. 42, 1062-1076 (2001).
32. Cleland, J. G., Coletta, A. P., Clark, A. L. & Cullington, D. Clinical trials update from the American College of Cardiology ADMiRE-HF, PRiMA, STiCH, REvERSE, iRiS, partial ventricular support, FiX-HF-5, vagal stimulation, REvivAL-3, pre-RELAX-AHF, ACTivE-A, HF-ACTiON, JUPiTER, AURORA, and OMEGA. Eur. J. Heart Fail. 11, 622-630 (2009).
33. Link, J. M. et al. PET measures of pre- and postsynaptic cardiac beta adrenergic function. Nucl. Med. Biol. 30, 795-803 (2003).
34. Tseng, H., Link, J. M., Stratton, J. R. & Caldwell, J. H. Cardiac receptor physiology and its application to clinical imaging: present and future. J. Nucl. Cardiol. 8, 390-409 (2001).
35. Accuracy of radiolabeled fatty acid analog, BMiPP, in the late detection of decreased blood flow to the heart (ZEUSS-ACS). NCT00585663. ClinicalTrials.gov [online] http://clinicaltrials. gov/ ct2/show/NCT00585663 (2009).
36. Cardiac sympathetic activity in patients with the apical ballooning syndrome. NCT00586183. ClinicalTrials.gov [online] http://clinicaltrials. gov/ct2/show/NCT00586183 (2007).
37. Battegay, E. J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 73, 333-346 (1995).
38. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 9, 653-660 (2003).
39. Brack, S. S., Dinkelborg, L. M. & Neri, D. Molecular targeting of angiogenesis for imaging and therapy. Eur. J. Nucl. Med. Mol. Imaging 31, 1327-1341 (2004).
40. Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G. & Thrall, J. H. imaging angiogenesis: applications and potential for drug development. J. Natl Cancer Inst. 97, 172-187 (2005).
41. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25 (1997).
42. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of vEGF and its receptors. Nat. Med. 9, 669-676 (2003).
43. Shweiki, D., itin, A., Soffer, D. & Keshet, E. vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992).
44. Brooks, P. C., Clark, R. A. & Cheresh, D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571 (1994).
45. Brooks, P. C. et al. integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994).
46. Haas, T. L. & Madri, J. A. Extracellular matrixdriven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc. Med. 9, 70-77 (1999).
47. Haas, T. L. et al. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 279, H1540-H1547 (2000).
48. Lu, E. et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 108, 97-103 (2003).
49. Cai, W. et al. PET of vascular endothelial growth factor receptor expression. J. Nucl. Med. 47, 2048-2056 (2006).
50. Rodriguez-Porcel, M. et al. imaging of vEGF receptor in a rat myocardial infarction model using PET. J. Nucl. Med. 49, 667-673 (2008).
51. Wagner, B. et al. Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomography. J. Am. Coll. Cardiol. 48, 2107-2115 (2006).
52. Sipkins, D. A. et al. Detection of tumor angiogenesis in vivo by alphavbeta3-targeted magnetic resonance imaging. Nat. Med. 4, 623-626 (1998).
53. Haubner, R. et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336 (2001).
54. Haubner, R. et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J. Nucl. Med. 40, 1061-1071 (1999).
55. Haubner, R. et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785 (2001).
56. Pfaff, M. et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha iib beta 3, alpha v beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem. 269, 20233-20238 (1994).
57. Harris, T. D. et al. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18, 627-641 (2003).
58. Sadeghi, M. M. et al. imaging ?v?3 integrin in vascular injury: does this reflect increased integrin expression or activation? Circulation 108 (17 Suppl.), 1868 (2003).
59. Meoli, D. F. et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Invest. 113, 1684-1691 (2004).
60. Kalinowski, L. et al. Targeted imaging of hypoxiainduced integrin activation in myocardium early after infarction. J. Appl. Physiol. 104, 1504-1512 (2008).
61. Bach-Gansmo, T. et al. integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J. Nucl. Med. 47, 1434-1439 (2006).
62. Edwards, D. et al. 99mTc-NC100692--a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation. Nucl. Med. Biol. 35, 365-375 (2008).
63. indrevoll, B. et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg. Med. Chem. Lett. 16, 6190-6193 (2006).
64. Kenny, L. M. et al. Phase i trial of the positronemitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med. 49, 879-886 (2008).
65. Hua, J. et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation 111, 3255-3260 (2005).
66. Lindsey, M. L. et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 290, H232-H239 (2006).
67. Dobrucki, L. W. et al. Serial noninvasive targeted imaging of peripheral angiogenesis: validation and application of a semiautomated quantitative approach. J. Nucl. Med. 50, 1356-1363 (2009).
68. Almutairi, A. et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc. Natl Acad. Sci. USA 106, 685-690 (2009).
69. Haubner, R. et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2, e70 (2005).
70. Liu, S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487 (2006).
71. Jaffer, F. A., Libby, P. & Weissleder, R. Molecular imaging of cardiovascular disease. Circulation 116, 1052-1061 (2007).
72. Sutton, M. G. & Sharpe, N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101, 2981-2988 (2000).
73. Chung, G. & Sinusas, A. J. imaging of matrix metalloproteinase activation and left ventricular remodeling. Curr. Cardiol. Rep. 9, 136-142 (2007).
74. Su, H. et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112, 3157-3167 (2005).
75. Liu, Y. H. et al. Hotspot quantification of myocardial focal tracer uptake from molecular targeted SPECT/CT images: experimental validation - art. no. 69150N. Proceedings-SPIE (The International Society for Optical Engineering) 6915 (Part 1), 69150N-69150N-8 (2008)
76. Nahrendorf, M. et al. Factor Xiii deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 113, 1196-1202 (2006).
77. Nahrendorf, M. et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXiii therapy and antithrombin use in myocardial infarction. Eur. Heart J. 29, 445-454 (2008).
78. Shirani, J. & Dilsizian, v. imaging left ventricular remodeling: targeting the neurohumoral axis. Nat. Clin. Pract. Cardiovasc. Med. 5 (Suppl. 2), S57-S62 (2008).
79. Dilsizian, v., Eckelman, W. C., Loredo, M. L., Jagoda, E. M. & Shirani, J. Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J. Nucl. Med. 48, 182-187 (2007).
80. Shirani, J., Narula, J., Eckelman, W. C., Narula, N. & Dilsizian, v. Early imaging in heart failure: exploring novel molecular targets. J. Nucl. Cardiol. 14, 100-110 (2007).
81. Trivedi, R. A. et al. identifying inflamed carotid plaques using in vivo USPiO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol. 26, 1601-1606 (2006).
82. Nahrendorf, M. et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117, 379-387 (2008).
83. Hyafil, F. et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 13, 636-641 (2007).
84. Schafers, M. et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 109, 2554-2559 (2004).
85. Zhang, J. et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 118, 1953-1960 (2008).
86. Sadeghi, M. M. et al. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation 110, 84-90 (2004).
87. Matter, C. M. et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ. Res. 95, 1225-1233 (2004).
88. von Lukowicz, T. et al. Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J. Nucl. Med. 48, 582-587 (2007).
89. Lederman, R. J. et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl. Med. Commun. 22, 747-753 (2001).
90. Zhu, Q., Piao, D., Sadeghi, M. M. & Sinusas, A. J. Simultaneous optical coherence tomography imaging and beta particle detection. Opt. Lett. 28, 1704-1706 (2003).